These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34669648)

  • 41. Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.
    Minari R; Bordi P; Del Re M; Facchinetti F; Mazzoni F; Barbieri F; Camerini A; Comin CE; Gnetti L; Azzoni C; Nizzoli R; Bortesi B; Rofi E; Petreni P; Campanini N; Rossi G; Danesi R; Tiseo M
    Lung Cancer; 2018 Jan; 115():21-27. PubMed ID: 29290257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mechanisms of osimertinib resistance and emerging treatment options.
    Schmid S; Li JJN; Leighl NB
    Lung Cancer; 2020 Sep; 147():123-129. PubMed ID: 32693293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.
    Akli A; Girard N; Fallet V; Rousseau-Bussac G; Gounant V; Friard S; Trédaniel J; Dujon C; Wislez M; Duchemann B; Giroux-Leprieur E
    Target Oncol; 2022 Nov; 17(6):675-682. PubMed ID: 36129569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acquired Resistance to Osimertinib in
    Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer.
    Lee J; Shim JH; Park WY; Kim HK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2019 Jan; 51(1):408-412. PubMed ID: 29807405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Histone Deacetylase 3 Inhibition Overcomes
    Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
    Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
    [No Abstract]   [Full Text] [Related]  

  • 50. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.
    Araki T; Kanda S; Horinouchi H; Ohe Y
    Jpn J Clin Oncol; 2023 Jun; 53(7):547-561. PubMed ID: 37279591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
    Ramalingam SS; Yang JC; Lee CK; Kurata T; Kim DW; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett JC; Thress KS; Jänne PA
    J Clin Oncol; 2018 Mar; 36(9):841-849. PubMed ID: 28841389
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
    Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.
    Tang ZH; Lu JJ
    Cancer Lett; 2018 Apr; 420():242-246. PubMed ID: 29425688
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Nakatani K; Yamaoka T; Ohba M; Fujita KI; Arata S; Kusumoto S; Taki-Takemoto I; Kamei D; Iwai S; Tsurutani J; Ohmori T
    Mol Cancer Ther; 2019 Jan; 18(1):112-126. PubMed ID: 30322949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
    Fuchs V; Roisman L; Kian W; Daniel L; Dudnik J; Nechushtan H; Goldstein I; Dvir A; Soussan-Gutman L; Grinberg R; Gillis R; Peled N
    Lung Cancer; 2021 Mar; 153():126-133. PubMed ID: 33486418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
    Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
    J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.
    Brown BP; Zhang YK; Westover D; Yan Y; Qiao H; Huang V; Du Z; Smith JA; Ross JS; Miller VA; Ali S; Bazhenova L; Schrock AB; Meiler J; Lovly CM
    Clin Cancer Res; 2019 Jun; 25(11):3341-3351. PubMed ID: 30796031
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.
    Du Y; Chen Y; Wang Y; Chen J; Lu X; Zhang L; Li Y; Wang Z; Ye G; Zhang G
    Mol Cancer Ther; 2022 Jul; 21(7):1060-1066. PubMed ID: 35499406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.
    Soejima K; Yasuda H; Hirano T
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):31-38. PubMed ID: 27885838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y
    Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.